Advanced Endometrial Cancer Clinical Trial
Official title:
A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV). This trial will be preceded by a safety lead-in study with up to 28 patients (the safety lead-in is a separate, free-standing protocol). Approximately 450 patients will be randomized equally (1:1) to receive EG-007 plus Len+Pem or Len+Pem alone. The randomization will be stratified by the following stratification factors: - Diagnosis Classification (advanced Stage III/IV vs. recurrent endometrial cancer) - ECOG score at baseline (0 vs 1) - Geographic region (Asia vs ROW)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04574284 -
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
|
Phase 2 | |
| Withdrawn |
NCT06046274 -
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05112991 -
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05106127 -
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
|
Phase 2 | |
| Completed |
NCT01289041 -
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05481645 -
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
|
Phase 2 |